MVMD’s patented Quicksol™️ solubility technology enhances new and existing compounds in the macrocyclic drug class that focus on improving livestock and aquatic species disease prevention and nutrition.
MVMD works with our partners to improve the health and productivity of animal and fish farming operations to support improved global human food supply chains.
Soluvec™ 1% is formulated to be administered at higher concentrations with a lower dose volume and provide the benefits of higher bioavailability compared to other commercially available formulations.
Introduced in 1981, Ivermectin has been studied for its dose-dependent pharmacokinetics across multiple administration routes. Depending on the species, the medication can be administered orally, intramuscularly (IM), subcutaneously (SC), or topically. The area under the curve (AUC) grows linearly when the dose increases, showing that pharmacokinetic characteristics are dose dependent.
MVMD’s Soluvec™ 1% has a solubility approximately 2,500 times greater than free Ivermectin. In numerous third-party conducted trials, when administered via intramuscular and subcutaneous routes, Soluvec™ 1% increased drug exposure, peak levels, and extended the duration of Ivermectin exposure in husbandry animals compared to commercially available Ivermectin in subcutaneous, intramuscular, and oral forms.
Compared to traditional methods, Soluvec™ demonstrated significant enhancement inIvermectin solubilization and bioavailability.
The published peer-reviewed study in the journal, Therapeutic Delivery, highlights the benefits of MVMD’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention.
In the resolubilized product, Soluvec™, Ivermectin was present as a mixof 28.0 nm particles and polysorbate-solubilized free Ivermectin. The totalconcentration was approximately 2,500 times greater than that of freeIvermectin in water.
In beagle dogs treated parenterally with Soluvec (subcutaneous or intramuscular dosing), total exposure of Ivermectin was ∼seven-times higher than in dogs receiving a non-solubilized Ivermectin tablet of the same dose orally.
Peak levels were higher and, most importantly for ease of treatment, duration of exposure was reliably greater with parenteral dosing; all Soluvec-treated animals had detectable IVM at 48 h, versus none of the non-solublized Ivermectin orally dosed animals.
Enhanced bioavailability of IVM in Soluvec™ suggests that a lower dose may achieve the desired therapeutic effects, potentially leading to reduced treatment costs and fewer side effects.
Research underscores favourable safety profile of Soluvec™, with minimal side effects generally observed in test subjects.
The results point to the possibility of easier treatment regimens and improved therapeutic outcomes not just for livestock but potentially for humans as well.
Access the article “Physical and Pharmacokinetic Characterization of Soluvec™, a novel, solvent-free aqueous Ivermectin formulation" here.
While MVMD’s current commercialization is focused on animal husbandry disease prevention, the solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a potential candidate for human injection. MVMD has plans to further evaluate the human applications in future R&D phases.
The well-being of humans, animals, and agriculture are a symbiotic ecosystem. The ecosystem must come together and work together to optimize our planet’s resources. At MVMD, we actively invest in and collaborate on pioneering biotechnologies that have the potential to revolutionize human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health.
MVMD offers organic Agrarius products which help farmers dramatically increase crop yields with less reliance on fertilizer and pesticides, reducing greenhouse gas emissions – which helps reduce their environmental impact.
MVMD’s Quicksome™ technology enhances existing and new nutraceutical products to help individuals achieve their wellness goals.
MVMD’s Quicksol™️ technology helps to enhance existing and new compounds that can improve livestock and aquatic species disease prevention and nutrition.
Stay plugged in on everything MVMD
Should you ever want to update your preferences or unsubscribe entirely, you can do so by contacting privacy@mvmd.com
